047920.KQ

HLB Pharmaceutical Co., Ltd is a South Korean pharmaceutical firm dedicated to the research and development of peptide-based drugs. Its product line encompasses a wide array of pharmaceutical preparations. These include medications for skeletal muscle relaxation, tranquilizing effects, antihistamine action, hypertension management, pain alleviation, anti-itching, astringent properties, anti-inflammatory relief, alimentary system support, metabolic regulation, ophthalmic conditions, local anesthesia, anti-arteriosclerosis, expectoration, fever reduction, analgesia, diabetes control, chemotherapy, peptic ulcer treatment, central nervous system issues, bacterial infections (antibiotics), digestive assistance, antacid needs, dental care, multivitamin supplementation, parasitic skin diseases, dermatological concerns, urogenital organ function, amino acid replacement, cough suppression, mucus thinning, parasitic worm elimination, diarrhea relief, circulatory system disorders, vitamin deficiencies, skin softening, hemorrhoid treatment, and liver ailments. Additionally, the company is actively developing CTT-004, an investigational therapy for ataxia associated with spinocerebellar degeneration, and offers Contract Manufacturing Organization (CMO) services. The enterprise, established in 1998, was formerly recognized as Mediforum Pharmaceutical Incorporation before adopting the name HLB Pharmaceutical Co., Ltd in October 2020. Its headquarters are located in Namyangju-Si, South Korea.